Aster DM Healthcare Limited has successfully concluded its board meeting and declared an interim dividend of Rs 3 per share for the current financial year 2025-26. The healthcare company's Board of Directors convened as scheduled on Thursday, March 26, 2026, and approved the interim dividend declaration following their earlier announcement to stock exchanges.

Board Meeting Outcome

The company's Board of Directors meeting, which was scheduled in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has resulted in the approval of interim dividend payment to shareholders. The board meeting commenced at 02:00 P.M. (IST) and concluded at 02:15 P.M. (IST), with the primary agenda of considering and approving interim dividend declaration for Financial Year 2025-26.

Dividend Payment Details

Shareholders holding shares on the established record date of Friday, April 3, 2026, will be eligible to receive the interim dividend of Rs 3 per share of Rs 10 each fully paid. The dividend shall be paid to shareholders within 30 days from the date of declaration of the interim dividend, as approved by the Board of Directors.

Tax Deduction at Source Provisions

Pursuant to the Finance Act 2020, dividend income will be taxable in the hands of shareholders with effect from April 1, 2020. The interim dividend declared by the Board of Directors shall be paid after deducting tax at source (TDS) in accordance with the provisions of the Income Tax Act, 1961. Members are requested to submit all requisite documents on or before April 06, 2026, to enable the company to determine the appropriate TDS rates as applicable. A separate communication regarding TDS provisions will be sent to shareholders in due course.

Regulatory Compliance and Communication

The dividend declaration demonstrates Aster DM Healthcare's commitment to maintaining transparency and regulatory compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was processed through proper channels with Company Secretary and Compliance Officer Hemish Purushottam overseeing the submission to both stock exchanges as required under listing regulations.

Aster DM Healthcare Limited has informed stock exchanges about receiving a GST order from tax authorities, disclosing details under SEBI regulations. The healthcare company received an order from the Assistant Commissioner, Kochi Commissionerate regarding alleged GST violations spanning multiple financial years.

GST Order Details

The order was issued under Section 74 of the Central Goods and Services Tax Act, 2017, and was received by the company on March 25, 2025. The order covers the period from FY 2019-20 to 2023-24 and relates to alleged non-payment of GST on insurance processing fees.

Nature of Alleged Violation

The tax authorities have alleged that the company failed to pay GST on insurance processing fees during the specified period. This has resulted in the issuance of an intimation of amount ascertained as payable under the GST Act, covering both tax liability and penalty components.

Company's Response and Impact Assessment

Aster DM Healthcare has clarified that the GST order will not have any material impact on the company's financial position, operations, or other business activities. The management has emphasized that the order is appealable under the existing legal framework.

The company has indicated its intention to pursue all available legal remedies under GST law to contest the order. This includes the option to file an appeal against the order issued by the Assistant Commissioner.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under SEBI Master Circular and related circulars regarding disclosure of orders received under tax laws.

The company has assured stakeholders that it will take necessary actions to address the matter through appropriate legal channels while maintaining its commitment to regulatory compliance.